ReviewOncogene2003
The future of antisense therapy: combination with anticancer treatments.
Review in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Target, silence, replace: a review on RNA-based drugs in modern medicine.Frontiers in cell and developmental biology · 2026Review
- Review
- CRISPR-Cas13d screens identify KILR, a breast cancer risk-associated lncRNA that regulates DNA replication and repair.Molecular cancer · 2024Article
- Simultaneous Targeting of Multiple oncomiRs with Phosphorothioate or PNA-Based Anti-miRs in Lymphoma Cell Lines.Pharmaceutical research · 2022Article
- MicroRNA-214-3p modified tetrahedral framework nucleic acids target survivin to induce tumour cell apoptosis.Cell proliferation · 2020Article
- Noncoding RNAs in cancer therapy resistance and targeted drug development.Journal of hematology & oncology · 2019Review
- Reprogramming Cells for Synergistic Combination Therapy with Nanotherapeutics against Uveal Melanoma.Biomimetics (Basel, Switzerland) · 2018Article
- Ki67 targeted strategies for cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Review
- Article
- Time depended Bcl-2 inhibition might be useful for a targeted drug therapy.Cancer cell international · 2015Review
- The effect of Bcl-2 siRNA combined with miR-15a oligonucleotides on the growth of Raji cells.Medical oncology (Northwood, London, England) · 2013Article
- Combined transfection of Bcl-2 siRNA and miR-15a oligonucleotides enhanced methotrexate-induced apoptosis in Raji cells.Cancer biology & medicine · 2013Article
- Downregulation of BCL11A by siRNA induces apoptosis in B lymphoma cell lines.Biomedical reports · 2013Article
- Functionalized halloysite nanotube-based carrier for intracellular delivery of antisense oligonucleotides.Nanoscale research letters · 2011Article
- The triple helix: 50 years later, the outcome.Nucleic acids research · 2008Review
- UTRN on chromosome 6q24 is mutated in multiple tumors.Oncogene · 2007Article
- [Combination treatment with antisense oligonucleotides and chemotherapy in vitro].Der Urologe. Ausg. A · 2005Article
- Targeting alternatively spliced sequence features for cancer diagnosis and therapeutics.Journal of gastroenterology · 2005Article
- Antitumor effects of radioiodinated antisense oligonuclide mediated by VIP receptor.Cancer gene therapy · 2005Article
- Selection of optimal antisense accessible sites of survivin and its application in treatment of gastric cancer.World journal of gastroenterology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current direction in cancer research is rational drug design, which is based on the evidence that transformed cells are characterized by alterations of genes devoted to the regulation of both cell proliferation and apoptosis. A variety of approaches have been carried out to develop new agents selective for cancer cells. Among these, antisense oligonucleotides (ASOs) are one of such class of new agents able to inhibit specifically the synthesis of a particular cancer-associated protein by binding to protein-encoding RNA, thereby preventing RNA function. In the past decade, several ASOs have been developed and tested in preclinical and clinical studies. Many have shown convincing in vitro reduction in target gene expression and promising activity against a wide variety of tumors. However, because of the multigenic alterations of tumors, the use of ASOs as single agents does not seem to be effective in the treatment of malignancies. Antisense therapy that interferes with signaling pathways involved in cell proliferation and apoptosis are particularly promising in combination with conventional anticancer treatment. An overview of the progress of ASOs used in combination therapy is provided.
Indexed as
Identifiers
14528283What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.